Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
1.96B
Enterprise Value
2.21B
Income
-65.67M
Sales
213.00M
Book/sh
1.31
Cash/sh
0.28
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
435
IPO
Nov 20, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
9.20
P/B
5.74
P/C
26.66
P/FCF
-
EV/EBITDA
119.97
EV/Sales
10.37
Quick Ratio
3.35
Current Ratio
4.66
Debt/Eq
0.91
LT Debt/Eq
0.89
Option/Short
Yes / Yes
EPS (ttm)
-0.45
EPS next Y
-0.08
EPS next Q
-0.04
EPS this Y
75.51%
EPS next Y
-6.11%
EPS next 5Y
44.71%
EPS past 3/5Y
- -
Sales past 3/5Y
-40.53% -8.15%
EPS Y/Y TTM
46.91%
Sales Y/Y TTM
10.77%
EPS Q/Q
47.45%
Sales Q/Q
10.14%
Insider Own
25.31%
Insider Trans
-0.08%
Inst Own
85.58%
Inst Trans
6.06%
ROA
-9.06%
ROE
-29.76%
ROIC
-17.71%
Gross Margin
38.87%
Oper. Margin
-17.16%
Profit Margin
-30.83%
SMA20
-1.42%
SMA50
1.88%
SMA200
38.37%
Trades
Shs Outstand
149.20M
Shs Float
111.47M
52W High
9.42 -19.96%
52W Low
2.80 169.29%
Volatility
5.97% 7.26%
ATR (14)
0.49
RSI (14)
49.82
Beta
0.63
Rel Volume
0.00
Avg Volume
3.21M
Volume
8
Perf Week
-5.99%
Perf Month
11.05%
Perf Quarter
31.36%
Perf Half Y
84.80%
Perf YTD
132.00%
Perf Year
107.14%
Perf 3Y
47.55%
Perf 5Y
-79.60%
Perf 10Y
-
Prev Close
7.54
Price
7.54
Change %
0.00%
Consensus
Buy
Avg. Price Target
$9.71
Implied Upside
+28.8%
Analysts15incl. previous ratings
Rating Distribution7 Buy · 7 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 12, 2026Upgrade
KEY logoKKeyBanc Capital Markets
Sector Weight → Overweight$11+45.9%
Oct 05, 2026Initiated
TD logoTTD Cowen
Buy$9+19.4%
Feb 26, 2025Downgrade
RRobert W. Baird
Outperform → Neutral$9 → $3-60.2%
Dec 19, 2024Initiated
GGuggenheim
Neutral
Dec 05, 2024Downgrade
GS logoGGoldman
Neutral → Sell$4.25-43.6%
Nov 14, 2024Initiated
WWolfe Research
Peer Perform
Nov 08, 2024Downgrade
WWilliam Blair
Outperform → Mkt Perform
Aug 28, 2024Initiated
WFC logoWWells Fargo
Overweight$10+32.6%
Aug 13, 2024Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$11 → $10+32.6%
Apr 10, 2024Initiated
CCraig Hallum
Buy$15+98.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORESHACK KURTGeneral CounselJun 10 '26Sale5.1025,000127,500335,767Jun 10 05:06 PM
ORESHACK KURTGeneral CounselJun 09 '26Sale5.0625,000126,500360,767Jun 10 05:06 PM
ORESHACK KURTOfficerJun 10 '26Proposed Sale5.1025,000127,500Jun 10 12:00 PM
ORESHACK KURTOfficerJun 09 '26Proposed Sale5.0625,000126,500Jun 09 10:31 AM
PRAHALAD MURALIFormer DirectorDec 23 '25Proposed Sale3.333,95113,138Dec 23 03:00 PM
Hopfield JessicaFormer DirectorDec 19 '25Proposed Sale3.4853,951187,526Dec 19 04:38 PM
LUCIER GREGORY TDirectorDec 05 '25Buy3.7051,472190,446106,595Dec 09 04:36 PM
LUCIER GREGORY TDirectorDec 08 '25Buy3.6748,528178,098155,123Dec 09 04:36 PM
Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm's brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Chairman of the BoardMr. Robert Andrew Eckert M.B.A.
CEO & DirectorMr. Bernd Brust
EVP & Chief Financial OfficerMr. Rajesh J. Asorpota
Executive VPMr. Kurt A. Oreshack J.D.
Executive VP & GM of Cygnus TechnologiesMs. Christine Dolan